Vyvgart®

Understanding Vyvgart®

Vyvgart® is used to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. It works by reducing harmful IgG autoantibodies that interfere with nerve-muscle communicationin gMG. Vyvgart® achieves this by blocking the Neonatal Fc receptor (FcRn), which normally helps maintain IgG levels in the blood. By lowering these damaging autoantibodies, Vyvgart® improves muscle strength and daily function, helping to prevent antibodies from disrupting nerve signals.

How Vyvgart® Works:

• Blocks FcRn, reducing harmful IgG autoantibodies
• Restores nerve-muscle communication, improving muscle strength
• Reduces symptoms and enhances daily function for individuals with gMG

FDA Approval:

• Vyvgart®: Approved on December 17, 2021, for anti-AChR antibody-positive generalized myasthenia gravis (gMG)

For more information, please visit the Vyvgart® patient website and speak with your healthcare provider to determine if Vyvgart® is the right treatment option for you.